SG11202109392YA - Thiazole derivatives as protein secretion inhibitors - Google Patents

Thiazole derivatives as protein secretion inhibitors

Info

Publication number
SG11202109392YA
SG11202109392YA SG11202109392YA SG11202109392YA SG11202109392YA SG 11202109392Y A SG11202109392Y A SG 11202109392YA SG 11202109392Y A SG11202109392Y A SG 11202109392YA SG 11202109392Y A SG11202109392Y A SG 11202109392YA SG 11202109392Y A SG11202109392Y A SG 11202109392YA
Authority
SG
Singapore
Prior art keywords
protein secretion
thiazole derivatives
secretion inhibitors
inhibitors
thiazole
Prior art date
Application number
SG11202109392YA
Other languages
English (en)
Inventor
Dustin Mcminn
Meera Rao
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of SG11202109392YA publication Critical patent/SG11202109392YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202109392YA 2019-02-28 2020-02-28 Thiazole derivatives as protein secretion inhibitors SG11202109392YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812013P 2019-02-28 2019-02-28
PCT/US2020/020419 WO2020176863A1 (fr) 2019-02-28 2020-02-28 Dérivés de thiazole en tant qu'inhibiteurs de sécrétion de protéines

Publications (1)

Publication Number Publication Date
SG11202109392YA true SG11202109392YA (en) 2021-09-29

Family

ID=70057287

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109392YA SG11202109392YA (en) 2019-02-28 2020-02-28 Thiazole derivatives as protein secretion inhibitors

Country Status (12)

Country Link
US (1) US20220153732A1 (fr)
EP (1) EP3930849A1 (fr)
JP (1) JP2022522014A (fr)
KR (1) KR20210143783A (fr)
CN (1) CN113993587A (fr)
AU (1) AU2020228307A1 (fr)
BR (1) BR112021017049A2 (fr)
CA (1) CA3131930A1 (fr)
IL (1) IL285908A (fr)
MX (1) MX2021010314A (fr)
SG (1) SG11202109392YA (fr)
WO (1) WO2020176863A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192828A1 (fr) 2020-08-04 2023-06-14 Nura Bio, Inc. Dérivés de pyridine substitués utiles comme inhibiteurs de sarm1
IL300736A (en) * 2020-08-31 2023-04-01 Kezar Life Sciences Protein secretion inhibitors
WO2022060812A1 (fr) 2020-09-16 2022-03-24 Nura Bio, Inc. Dérivés de pyridine substitués utiles comme inhibiteurs de sarm1
MX2023003443A (es) * 2020-09-24 2023-06-22 Shanghai Yao Yuan Biotechnology Co Ltd Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
WO2022159980A1 (fr) * 2021-01-25 2022-07-28 Athos Therapeutics, Inc. Composés pharmaceutiques et leurs procédés de fabrication et méthodes d'utilisation
CN113149881B (zh) * 2021-03-04 2022-07-19 宁波大学 一种手性衍生化试剂及其制备方法和应用
CN118103045A (zh) * 2021-04-19 2024-05-28 上海药苑生物科技有限公司 用于治疗川崎病的α蛋白激酶1抑制剂
EP4377298A1 (fr) * 2021-07-27 2024-06-05 Gate Bioscience, Inc. Inhibiteurs de sécrétion de protéines
WO2023009663A1 (fr) * 2021-07-28 2023-02-02 Nura Bio, Inc. Dérivés de pyridine substitués en tant qu'inhibiteurs de sarm1
WO2023143603A1 (fr) * 2022-01-29 2023-08-03 Shanghai Yao Yuan Biotechnology Co., Ltd. Inhibiteurs de l'alpha protéine kinase 1 destinés à être utilisés dans le traitement de l'athérosclérose et de maladies associées
AR128634A1 (es) * 2022-02-28 2024-05-29 Kezar Life Sciences Inhibidores de sec61 y uso de los mismos
WO2024002270A1 (fr) * 2022-06-29 2024-01-04 Shanghai Yao Yuan Biotechnology Co., Ltd. Inhibiteurs de la protéine kinase 1 alpha destinés à être utilisés dans le traitement de maladies rénales et de maladies liées au rein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US7265134B2 (en) * 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2561977A1 (fr) * 2004-03-30 2005-10-13 Chiron Corporation Derives du thiophene substitues en tant qu'agents anticancereux
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
JP2012525336A (ja) * 2009-04-27 2012-10-22 エラン ファーマシューティカルズ，インコーポレイテッド α−４インテグリンのピリジノンアンタゴニスト
WO2014145642A2 (fr) * 2013-03-15 2014-09-18 The Johns Hopkins University Inhibiteurs de nrf2 à petite molécule pour traitement anticancéreux

Also Published As

Publication number Publication date
EP3930849A1 (fr) 2022-01-05
MX2021010314A (es) 2021-11-12
TW202045489A (zh) 2020-12-16
US20220153732A1 (en) 2022-05-19
WO2020176863A1 (fr) 2020-09-03
IL285908A (en) 2021-10-31
CA3131930A1 (fr) 2020-09-03
CN113993587A (zh) 2022-01-28
JP2022522014A (ja) 2022-04-13
AU2020228307A1 (en) 2021-09-23
BR112021017049A2 (pt) 2022-02-08
KR20210143783A (ko) 2021-11-29

Similar Documents

Publication Publication Date Title
IL285908A (en) Thiazole derivatives as inhibitors of protein secretion
IL277006A (en) CD73 inhibitors
EP3843714A4 (fr) Inhibiteurs de cd73
IL304348A (en) cd73 inhibitors
IL283486A (en) Thiazole derivatives kill microorganisms
EP3697787A4 (fr) Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase
ZA202000107B (en) Aminothiazole compounds as protein kinase inhibitors
IL289622A (en) bcl-2 protein inhibitors
SG11202110534QA (en) Cd73 inhibitors
EP3924351A4 (fr) Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
ZA202106024B (en) Heterocyclic derivatives
EP3746430A4 (fr) Inhibiteurs de protéine arginine déiminases
IL290314A (en) Quinolines as protein kinase inhibitors
IL283802A (en) Protein preparations with a high concentration to prevent tissue adhesion
EP3947371C0 (fr) Dérivés du thiazole microbiocides
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
EP3680343A4 (fr) Procédé d'augmentation de la sécrétion de protéine recombinante
IL281720A (en) HMGB1 protein derivatives to remove biofilms
EP3947369A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de bcr-abl
EP3981469A4 (fr) Agent thérapeutique contre la goutte ou l'hyperuricémie
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
EP3822270A4 (fr) Nouveau dérivé hétérocyclique
TWI845624B (zh) 蛋白分泌抑制劑
EP3522881A4 (fr) Inhibiteurs de protéine du groupe b1 à mobilité élevée
IL310370A (en) Inhibitors of protein expression